CD20 / MS4A1蛋白產(chǎn)品信息

別名: CD20, MS4A1
表達(dá)方式: 
A DNA sequence encoding the cynomolgus CD20 (F7D2Q2) (Glu213-Pro297)  was expressed with a polyhistidine tag at the C-terminus.
種屬: Cynomolgus
表達(dá)宿主: Human Cells

CD20 / MS4A1 Protein QC Testing

純度: (97.6+1.4) % as determined by SDS-PAGE SDS-PAGE
內(nèi)**: < 1.0 EU per μg of the protein as determined by the LAL method
穩(wěn)定性: Samples are stable for up to twelve months from date of receipt at -70℃
預(yù)測(cè)N端: Glu 213
分子量: 
The recombinant cynomolgus CD20 comprises 96 amino acids and has a calculated molecular mass of 11.2 KDa. The apparent molecular mass of it is approximately 24-27 and 18 KDa  in SDS-PAGE under reducing conditions.
緩沖液: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Please contact us for any concerns or special requirements.

CD20 / MS4A1 Protein Usage Guide

儲(chǔ)存方法: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CD20 / MS4A1蛋白背景綜述

B-lymphocyte antigen CD20, also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is a multi-pass membrane protein which belongs to theMS4A family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed on all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

參考文獻(xiàn)

Tedder TF. et al.,1988, Proc Natl Acad Sci. 85 (1): 208-12.
Cragg MS. et al., 2005, Curr Dir Autoimmun. 8: 140-74.
Fang D. et al., 2005, Cancer Res. 65 (20): 9328-37.
Teeling JL. et al., 2006, J Immunol. 177: 362-71.

規(guī)格：10ug

關(guān) 鍵 詞：Cynomolgus CD20 / MS4A1 (aa 213-297) Protein,技術(shù)資料,廠家現(xiàn)貨，實(shí)驗(yàn)室耗材，生化試劑，上海創(chuàng)賽，博飛美科，實(shí)驗(yàn)儀器，廠家

CANSPEC品質(zhì)提供的Cynomolgus CD20 / MS4A1 (aa 213-297) Protein|技術(shù)資料|廠家現(xiàn)貨性能**，其優(yōu)良的品質(zhì)滿足您不同實(shí)驗(yàn)的多種需求。

本產(chǎn)品由上海創(chuàng)賽品質(zhì)提供，歡迎咨詢國(guó)內(nèi)免費(fèi)服務(wù)專線：400-608-7598，更多產(chǎn)品信息請(qǐng)登錄www.ahbcpqn.cn 或 www.4006087598.com